| Symbol | SDEV |
|---|---|
| Name | NOVABAY PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2000 POWELL STREET,SUITE 1150, EMERYVILLE, California, 94608, United States |
| Telephone | +1 510 899-8800 |
| Fax | — |
| — | |
| Website | https://www.novabay.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001389545 |
| Description | NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. Additional info from NASDAQ: |
Director Kazley Michael John 🟡 adjusted position in 22.6M shares (1 derivative) of Stablecoin Development Corp (SDEV) at $1.09 Transaction Date: Jun 15, 2026 | Filing ID: 021026
Read moreFramework Ventures IV L.P. 🟡 adjusted position in 22.6M shares (1 derivative) of Stablecoin Development Corp (SDEV) at $1.09 Transaction Date: Jun 15, 2026 | Filing ID: 021025
Read moreDirector R01 Fund LP 🟡 adjusted position in 22.6M shares (1 derivative) of Stablecoin Development Corp (SDEV) at $1.09 Transaction Date: Jun 15, 2026 | Filing ID: 021024
Read moreNew Form SCHEDULE 13D/A - Stablecoin Development Corp <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001437749-26-021023 <b>Size:</b> 21 KB
Read moreNew Form SCHEDULE 13D/A - Stablecoin Development Corp <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001437749-26-021022 <b>Size:</b> 19 KB
Read more(99% Neutral) NOVABAY PHARMACEUTICALS, INC. (SDEV) Announces Business Combination
Read moreNew Form SCHEDULE 13D - Stablecoin Development Corp <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001437749-26-018547 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G - Stablecoin Development Corp <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 0001193125-26-237063 <b>Size:</b> 19 KB
Read more(99% Neutral) NOVABAY PHARMACEUTICALS, INC. (SDEV) Reports Q2 2026 Financial Results
Read moreStablecoin Development Corporation Reports First Quarter 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03861728 | Viral Conjunctivitis Treatment Study | Na | Viral Conjunctivitis | Terminated | 2018-11-14 | 2020-02-08 | ClinicalTrials.gov |
| NCT02938078 | Ocular Comfort and Inflammation in Lid Hygiene Therapy | Na | Blepharitis | Terminated | 2016-10-01 | 2018-08-24 | ClinicalTrials.gov |
| NCT02455895 | Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora | Na | Sebaceous Gland Diseases | Unknown | 2015-05-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02130518 | Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency | Phase2 | Urinary Catheter Blockage and Encrustation | Unknown | 2014-09-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01877694 | Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conj… | Phase2 | Bacterial Conjunctivitis | Completed | 2013-06-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01670032 | Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.… | Phase2 | Impetigo | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01532336 | Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis | Phase2 | Adenoviral Conjunctivitis | Completed | 2012-05-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01243125 | Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation | Phase2 | Urinary Catheter Blockage and Encrustation | Completed | 2010-11-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01367314 | Safety and Efficacy of Topical NVC-422 Gel in Impetigo | Phase2 | Impetigo | Completed | 2009-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00781339 | Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients | Phase2 | Asymptomatic Bacteriuria | Completed | 2008-10-01 | 2010-03-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Avenova Lid Cleanser | Other | Approved | Blepharitis | TERMINATED | NCT02938078 |
| NVC-422 | Other | Phase PHASE2 | Impetigo | COMPLETED | NCT01367314 |
| Sterile normal saline, 0.9% | Other | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | COMPLETED | NCT01243125 |
| NVC-422, 0.2% | Other | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | COMPLETED | NCT01243125 |
| Placebo Comparator: CD07223 vehicle gel TID | Other | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Placebo Comparator: CD07223 vehicle gel BID | Other | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Experimental: CD07223 1.5% Topical Gel TID | Other | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Experimental: CD07223 1.5 % Topical Gel BID | Other | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| iLid Cleanser | Other | Approved | Sebaceous Gland Diseases | UNKNOWN | NCT02455895 |
| Auriclosene Vehicle | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT01877694 |
| Auriclosene Solution 0.3% | Other | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT01877694 |
| NVC-422 Vehicle Solution | Other | Phase PHASE2 | Adenoviral Conjunctivitis | COMPLETED | NCT01532336 |
| NVC-422 Solution, 0.3% | Other | Phase PHASE2 | Adenoviral Conjunctivitis | COMPLETED | NCT01532336 |
| Auriclosene Vehicle Solution | Other | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | UNKNOWN | NCT02130518 |
| Auriclosene Irrigation Solution, 0.2% | Other | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | UNKNOWN | NCT02130518 |
| Placebo | Other | Approved | Viral Conjunctivitis | TERMINATED | NCT03861728 |
| 0.01% Hypochlorous acid | Other | Approved | Viral Conjunctivitis | TERMINATED | NCT03861728 |
| Placebo | OTHER | Approved | Viral Conjunctivitis | TERMINATED | NCT03861728 |
| 0.01% Hypochlorous acid | DEVICE | Approved | Viral Conjunctivitis | TERMINATED | NCT03861728 |
| Avenova Lid Cleanser | DEVICE | Approved | Blepharitis | TERMINATED | NCT02938078 |
| iLid Cleanser | DEVICE | Approved | Sebaceous Gland Diseases | UNKNOWN | NCT02455895 |
| NVC-422 | DRUG | Phase PHASE2 | Impetigo | COMPLETED | NCT01367314 |
| Auriclosene Vehicle Solution | DRUG | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | UNKNOWN | NCT02130518 |
| Auriclosene Irrigation Solution, 0.2% | DRUG | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | UNKNOWN | NCT02130518 |
| Auriclosene Vehicle | DRUG | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT01877694 |
| Auriclosene Solution 0.3% | DRUG | Phase PHASE2 | Bacterial Conjunctivitis | COMPLETED | NCT01877694 |
| Placebo Comparator: CD07223 vehicle gel TID | DRUG | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Placebo Comparator: CD07223 vehicle gel BID | DRUG | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Experimental: CD07223 1.5% Topical Gel TID | DRUG | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| Experimental: CD07223 1.5 % Topical Gel BID | DRUG | Phase PHASE2 | Impetigo | COMPLETED | NCT01670032 |
| NVC-422 Vehicle Solution | DRUG | Phase PHASE2 | Adenoviral Conjunctivitis | COMPLETED | NCT01532336 |
| NVC-422 Solution, 0.3% | DRUG | Phase PHASE2 | Adenoviral Conjunctivitis | COMPLETED | NCT01532336 |
| Sterile normal saline, 0.9% | DRUG | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | COMPLETED | NCT01243125 |
| NVC-422, 0.2% | DRUG | Phase PHASE2 | Urinary Catheter Blockage and Encrustation | COMPLETED | NCT01243125 |
| sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate | DRUG | Phase PHASE2 | Asymptomatic Bacteriuria | COMPLETED | NCT00781339 |